StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research report on Thursday, November 14th.

Trevena Price Performance

Shares of TRVN opened at $1.50 on Friday. Trevena has a 1 year low of $1.13 and a 1 year high of $19.23. The business has a 50-day moving average of $1.75 and a 200-day moving average of $3.72. The company has a market capitalization of $1.29 million, a price-to-earnings ratio of -0.03 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million during the quarter. As a group, sell-side analysts anticipate that Trevena will post -23.04 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.